Literature DB >> 22824480

Mechanisms of disease progression in NASH: new paradigms.

Brittany N Bohinc1, Anna Mae Diehl.   

Abstract

The incidence of nonalcoholic fatty liver disease is increasing at an astonishing rate in the US population. Although only a small proportion of these patients develop steatohepatitis (NASH), those who do have a greater likelihood of developing end-stage liver disease and complications. Research on liver fibrosis and NASH progression shows that hedgehog (Hh) is reactivated after liver injury to assist in liver repair and regeneration. When the process of tissue repair and regeneration is prolonged or when Hh ligand and related genes are aberrantly regulated and excessive, tissue repair goes awry and NASH progresses to cirrhosis and hepatocellular carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824480     DOI: 10.1016/j.cld.2012.05.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  38 in total

1.  Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer.

Authors:  Koji Matsuo; Marc R Gualtieri; Sigita S Cahoon; Carrie E Jung; Richard J Paulson; Donna Shoupe; Laila I Muderspach; Akihiko Wakatsuki; Jason D Wright; Lynda D Roman
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

Review 2.  Antifibrotic therapies in the liver.

Authors:  W Z Mehal; D Schuppan
Journal:  Semin Liver Dis       Date:  2015-05-14       Impact factor: 6.115

3.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

4.  Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.

Authors:  Varun Chandrashekaran; Suvarthi Das; Ratanesh Kumar Seth; Diptadip Dattaroy; Firas Alhasson; Gregory Michelotti; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Biochim Biophys Acta       Date:  2015-10-22

5.  Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Xiaobo Wang; Ze Zheng; Jorge Matias Caviglia; Kathleen E Corey; Tina M Herfel; Bishuang Cai; Ricard Masia; Raymond T Chung; Jay H Lefkowitch; Robert F Schwabe; Ira Tabas
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

6.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

7.  Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E.

Authors:  Ning Ma; Yanqi Hou; Heidi Coia; Marcin D Dyba; Ying Fu; M Idalia Cruz; Carlos Benitez; Garrett T Graham; Justine N McCutcheon; Yun-Ling Zheng; Bing Sun; Bhaskar V Kallakury; Junfeng Ma; Hong-Bin Fang; Deborah L Berry; Vinona Muralidaran; Fung-Lung Chung
Journal:  Cancer Prev Res (Phila)       Date:  2018-08-21

8.  M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.

Authors:  Ratanesh Kumar Seth; Suvarthi Das; Sahar Pourhoseini; Diptadip Dattaroy; Stephen Igwe; Julie Basu Ray; Daping Fan; Gregory A Michelotti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

Review 9.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

Review 10.  Immune cells and metabolic dysfunction.

Authors:  Ashley Eheim; Dasa Medrikova; Stephan Herzig
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.